200 related articles for article (PubMed ID: 17636851)
1. Pharmaceutical policies: effects of financial incentives for prescribers.
Sturm H; Austvoll-Dahlgren A; Aaserud M; Oxman AD; Ramsay C; Vernby A; Kösters JP
Cochrane Database Syst Rev; 2007 Jul; (3):CD006731. PubMed ID: 17636851
[TBL] [Abstract][Full Text] [Related]
2. Pharmaceutical policies: effects of financial incentives for prescribers.
Rashidian A; Omidvari AH; Vali Y; Sturm H; Oxman AD
Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD006731. PubMed ID: 26239041
[TBL] [Abstract][Full Text] [Related]
3. Pharmaceutical policies: effects of cap and co-payment on rational drug use.
Austvoll-Dahlgren A; Aaserud M; Vist G; Ramsay C; Oxman AD; Sturm H; Kösters JP; Vernby A
Cochrane Database Syst Rev; 2008 Jan; (1):CD007017. PubMed ID: 18254125
[TBL] [Abstract][Full Text] [Related]
4. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
[TBL] [Abstract][Full Text] [Related]
5. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
Aaserud M; Dahlgren AT; Kösters JP; Oxman AD; Ramsay C; Sturm H
Cochrane Database Syst Rev; 2006 Apr; (2):CD005979. PubMed ID: 16625648
[TBL] [Abstract][Full Text] [Related]
6. Pharmaceutical policies: effects of educational or regulatory policies targeting prescribers.
Suleman F; Movik E
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31721159
[TBL] [Abstract][Full Text] [Related]
7. Pharmaceutical policies: effects of cap and co-payment on rational use of medicines.
Luiza VL; Chaves LA; Silva RM; Emmerick IC; Chaves GC; Fonseca de Araújo SC; Moraes EL; Oxman AD
Cochrane Database Syst Rev; 2015 May; 2015(5):CD007017. PubMed ID: 25966337
[TBL] [Abstract][Full Text] [Related]
8. The effect of financial incentives on the quality of health care provided by primary care physicians.
Scott A; Sivey P; Ait Ouakrim D; Willenberg L; Naccarella L; Furler J; Young D
Cochrane Database Syst Rev; 2011 Sep; (9):CD008451. PubMed ID: 21901722
[TBL] [Abstract][Full Text] [Related]
9. Pharmaceutical policies: effects of policies regulating drug marketing.
Fulone I; Cadogan C; Barberato-Filho S; Bergamaschi CC; Mazzei LG; Lopes LP; Silva MT; Lopes LC
Cochrane Database Syst Rev; 2023 Jun; 6(6):CD013780. PubMed ID: 37288951
[TBL] [Abstract][Full Text] [Related]
10. Financial arrangements for health systems in low-income countries: an overview of systematic reviews.
Wiysonge CS; Paulsen E; Lewin S; Ciapponi A; Herrera CA; Opiyo N; Pantoja T; Rada G; Oxman AD
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011084. PubMed ID: 28891235
[TBL] [Abstract][Full Text] [Related]
11. Pharmaceutical policies: effects of regulating drug insurance schemes.
Pantoja T; Peñaloza B; Cid C; Herrera CA; Ramsay CR; Hudson J
Cochrane Database Syst Rev; 2022 May; 5(5):CD011703. PubMed ID: 35502614
[TBL] [Abstract][Full Text] [Related]
12. European healthcare policies for controlling drug expenditure.
Ess SM; Schneeweiss S; Szucs TD
Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
[TBL] [Abstract][Full Text] [Related]
13. International experience in controlling pharmaceutical expenditure: influencing patients and providers and regulating industry - a systematic review.
Lee IH; Bloor K; Hewitt C; Maynard A
J Health Serv Res Policy; 2015 Jan; 20(1):52-9. PubMed ID: 25092883
[TBL] [Abstract][Full Text] [Related]
14. Government regulation of private health insurance.
Motaze NV; Chi PC; Ongolo-Zogo P; Ndongo JS; Wiysonge CS
Cochrane Database Syst Rev; 2021 Feb; 2(2):CD011512. PubMed ID: 33617665
[TBL] [Abstract][Full Text] [Related]
15. Pharmaceutical policies: effects of restrictions on reimbursement.
Green CJ; Maclure M; Fortin PM; Ramsay CR; Aaserud M; Bardal S
Cochrane Database Syst Rev; 2010 Aug; 2010(8):CD008654. PubMed ID: 20687098
[TBL] [Abstract][Full Text] [Related]
16. Challenges to achieving value in drug spending in a decentralized country: the Spanish case.
Antoñanzas F
Value Health; 2003; 6 Suppl 1():S52-63. PubMed ID: 12846926
[TBL] [Abstract][Full Text] [Related]
17. The drug budget silo mentality: the French case.
Le Pen C
Value Health; 2003; 6 Suppl 1():S10-9. PubMed ID: 12846922
[TBL] [Abstract][Full Text] [Related]
18. Using disease management and market reforms to address the adverse economic effects of drug budgets and price and reimbursement regulations in Germany.
Schwermann T; Greiner W; v d Schulenburg JM
Value Health; 2003; 6 Suppl 1():S20-30. PubMed ID: 12846923
[TBL] [Abstract][Full Text] [Related]
19. Target payments in primary care: effects on professional practice and health care outcomes.
Giuffrida A; Gosden T; Forland F; Kristiansen IS; Sergison M; Leese B; Pedersen L; Sutton M
Cochrane Database Syst Rev; 2000; 1999(3):CD000531. PubMed ID: 10908475
[TBL] [Abstract][Full Text] [Related]
20. A prescribing incentive scheme for non-fundholding general practices: an observational study.
Bateman DN; Campbell M; Donaldson LJ; Roberts SJ; Smith JM
BMJ; 1996 Aug; 313(7056):535-8. PubMed ID: 8789984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
